Table 3 The relationship between validated ratios, scores and survival in patients undergoing surgery for colon cancer (n = 801)

From: The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores

 

Univariate

Multivariate Adjusted for TNM stage

Univariate

Multivariate Adjusted for TNM stage

 

AUC (95% CI)

CSS HR (95% CI)

p value

CSS HR (95% CI)

p value

AUC (95% CI)

OS HR (95% CI)

p value

OS HR (95% CI)

p value

TNM stage

          

 I (n = 116)

0.649 (0.559–0.740)

    

0.569 (0.477–0.661)

    

 II (n = 391)

 

4.39 (1.78–10.85)

0.001

   

1.73 (1.16–2.57)

0.007

  

 III (n = 294)

 

9.86 (4.02–24.17)

<0.001

   

2.54 (1.70–3.79)

<0.001

  

NLR/NLS

 NLR <3 (n = 388)

0.577 (0.529–0.624)

    

0.594 (0.554–0.633)

    

 NLR 3–5 (n = 260)

 

1.22 (0.87–1.72)

0.251

1.28 (0.91–1.80)

0.152

 

1.21 (0.95–1.53)

0.118

1.26 (0.99–1.59)

0.061

 NLR >5 (n = 153)

 

2.06 (1.46–2.92)

<0.001

2.11 (1.50–3.00)

<0.001

 

1.85 (1.44–2.37)

<0.001

1.88 (1.46–2.42)

<0.001

 NLS 0 (n = 421)

0.566 (0.519–0.613)

    

0.586 (0.546–0.626)

    

 NLS 1 (n = 325)

 

1.49 (1.10–2.01)

0.010

1.57 (1.16–2.12)

0.003

 

1.45 (1.17–1.79)

0.001

1.49 (1.21–1.85)

<0.001

 NLS 2 (n = 55)

 

2.01 (1.22–3.30)

0.006

1.85 (1.12–3.05)

0.016

 

1.68 (1.15–2.46)

0.007

1.59 (1.09–2.33)

0.016

PLR/PLSa

 PLR ≤150 (n = 237)

0.538 (0.486–0.589)

    

0.555 (0.512–0.598)

    

 PLR >150 (n = 445)

 

1.31 (0.92–1.86)

0.141

1.20 (0.84–1.70)

0.326

 

1.26 (0.98–1.63)

0.073

1.20 (0.93–1.55)

0.166

 PLS 0 (n = 351)

0.578 (0.525–0.631)

    

0.586 (0.542–0.629)

    

 PLS 1 (n = 283)

 

1.39 (0.98–1.96)

0.061

1.33 (0.94–1.88)

0.106

 

1.34 (1.05–1.70)

0.020

1.29 (1.01–1.65)

0.040

 PLS 2 (n = 48)

 

2.77 (1.67–4.59)

<0.001

2.42 (1.46–4.01)

0.001

 

2.16 (1.46–3.18)

<0.001

1.94 (1.31–2.87)

0.001

LMR/LMSb

 LMR ≥2.4 (n = 161)

0.613 (0.539–0.688)

    

0.590 (0.528–0.652)

    

 LMR <2.4 (n = 252)

 

2.62 (1.61–4.27)

<0.001

2.49 (1.53–4.06)

<0.001

 

2.08 (1.44–3.00)

<0.001

1.99 (1.38–2.87)

<0.001

 LMS 0 (n = 214)

0.605 (0.528–0.681)

    

0.585 (0.522–0.648)

    

 LMS 1 (n = 169)

 

1.69 (0.99–2.86)

0.051

1.65 (0.97–2.81)

0.064

 

1.47 (0.99–2.17)

0.058

1.41 (0.95–2.10)

0.088

 LMS 2 (n = 30)

 

3.68 (1.81–7.49)

<0.001

3.67 (1.80–7.49)

<0.001

 

2.81 (1.59–4.95)

<0.001

2.76 (1.56–4.88)

<0.001

NPSa

 NPS 0 (n = 491)

0.580 (0.526–0.634)

    

0.576 (0.532–0.619)

    

 NPS 1 (n = 140)

 

1.76 (1.22–2.55)

0.003

1.47 (1.02–2.13)

0.042

 

1.64 (1.26–2.14)

<0.001

1.47 (1.12–1.92)

0.005

 NPS 2 (n = 51)

 

2.50 (1.52–4.10)

<0.001

2.14 (1.30–3.51)

0.003

 

1.83 (1.24–2.70)

0.002

1.65 (1.12–2.44)

0.011

CAR/mGPS

 CAR ≤0.22 (n = 412)

0.582 (0.536–0.628)

    

0.603 (0.563–0.642)

    

 CAR >0.22 (n = 389)

 

1.88 (1.40–2.51)

<0.001

1.76 (1.31–2.35)

<0.001

 

1.88 (1.53–2.31)

<0.001

1.84 (1.49–2.26)

<0.001

 mGPS 0 (n = 474)

0.591 (0.544–0.639)

    

0.623 (0.582–0.663)

    

 mGPS 1 (n = 173)

 

1.35 (0.95–1.94)

0.099

1.22 (0.85–1.75)

0.282

 

1.49 (1.17–1.90)

0.001

1.44 (1.12–1.84)

0.004

 mGPS 2 (n = 154)

 

2.47 (1.77–3.46)

<0.001

2.31 (1.65–3.25)

<0.001

 

2.32 (1.81–2.99)

<0.001

2.28 (1.76–2.95)

<0.001

  1. an = 682.
  2. bn = 413.
  3. AUC area under the curve, CI confidence interval, HR hazard ratio, CSS cancer-specific survival, OS overall survival, TNM tumour node metastasis, NLR neutrophil–lymphocyte ratio, NLS neutrophil–lymphocyte score, CAR C-reactive protein albumin ratio, mGPS modified Glasgow prognostic score, NPS neutrophil–platelet score, LMS lymphocyte–monocyte score, LMR lymphocyte–monocyte ratio, PLR platelet–lymphocyte ratio, PLS platelet–lymphocyte score
Back to article page